DERM Stock Overview
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Journey Medical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.16 |
| 52 Week High | US$8.11 |
| 52 Week Low | US$2.33 |
| Beta | 0.91 |
| 11 Month Change | 16.48% |
| 3 Month Change | -7.36% |
| 1 Year Change | 93.99% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -45.68% |
Recent News & Updates
Recent updates
Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden
Sep 14
Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
May 06Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
Mar 11Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Jan 18Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Nov 10US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results
May 12Shareholder Returns
| DERM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 10.3% | 1.3% | 4.2% |
| 1Y | 94.0% | 18.8% | 24.4% |
Return vs Industry: DERM exceeded the US Pharmaceuticals industry which returned 19% over the past year.
Return vs Market: DERM exceeded the US Market which returned 24.4% over the past year.
Price Volatility
| DERM volatility | |
|---|---|
| DERM Average Weekly Movement | 9.7% |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DERM has not had significant price volatility in the past 3 months.
Volatility Over Time: DERM's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 41 | Claude Maraoui | journeymedicalcorp.com |
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.
Journey Medical Corporation Fundamentals Summary
| DERM fundamental statistics | |
|---|---|
| Market cap | US$106.95m |
| Earnings (TTM) | US$843.00k |
| Revenue (TTM) | US$77.68m |
126.9x
P/E Ratio1.4x
P/S RatioIs DERM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DERM income statement (TTM) | |
|---|---|
| Revenue | US$77.68m |
| Cost of Revenue | US$25.80m |
| Gross Profit | US$51.88m |
| Other Expenses | US$51.04m |
| Earnings | US$843.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.041 |
| Gross Margin | 66.79% |
| Net Profit Margin | 1.09% |
| Debt/Equity Ratio | 201.4% |
How did DERM perform over the long term?
See historical performance and comparison